Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Abandons Proposal For Interactive, “Pre-Decisional” IDE

This article was originally published in The Gray Sheet

Executive Summary

The agency finalized a guidance document on investigational device exemption review decisions, dropping a proposal to establish a new, interactive “pre-decisional” IDE process. Industry had been skeptical that the proposed program would improve efficiency of study reviews, and worries that it would require a lot of FDA resources.


Related Content

FDA Updates Its Criteria For Medicare Coverage Of Device Trials
CDRH’s Owen Faris: New Clinical Trials Program Will Speed Up IDE Approvals
Industry Asks FDA To Relay Study Design Concerns Separately From IDE Decisions
The Pre-Decisional IDE: FDA’s New Proposal To Help Studies Get Started Right
FDA To Re-Issue Draft Guidance On Investigational Device Exemption Standards
Jumpstarting U.S. Device Trials? FDA Makes Effort In New Draft Guidelines





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts